TrialBMC cancer2015

Feasibility study of docetaxel plus bevacizumab as first line therapy for elderly patients with advanced non-small-cell lung cancer: Thoracic Oncology Research Group (TORG) 1014.

Yusuke Takagi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.